Prostate Cancer Diagnostics and Therapy Market Snapshot
|Study Period:||2018 - 2026|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The prostate cancer diagnostics and therapy market was expected to register a CAGR of nearly 6.1% during the forecast period, 2021-2026.
Cancer diagnosis and treatment care are hard hit by the sudden emergence of the COVID-19 infection due to the halt in diagnostic procedures and surgical procedures. Moreover, as per many studies, cancer patients, especially prostate cancer patients, are more susceptible to coronavirus than individuals without cancer, as they are in an immunosuppressive state caused by the malignancy and anticancer treatment. Thus, they are majorly suggested to stay at home and avoid all non-emergent diagnoses and treatment. According to the Union for International Cancer Control (UICC), there is a significant decrease in cancer diagnostics rates in the United States during the pandemic. This is expected to impact the market growth. However, this negative growth is anticipated to persist for a short duration.
The major factor attributing to the growth of the market studied is an aging population and a high prevalence rate of prostate cancer. Prostate cancer is the second most common type of cancer in the male population. About 80% of men who reach 80 years of age are diagnosed with it. As per the data published by Globocan 2020, the prevalence of prostate cancer was found to be 1,414,259, or 7.3% of the total cancer cases worldwide. As prostate cancer is more common in the elderly population, the rising aging is population in the world is also expected to propel market growth. For instance, as per World Population Ageing Report 2019, there were 703 million people aged 65 years or over in the world in 2019, and this number of older persons is projected to double and reach 1.5 billion in 2050. Several government bodies are also taking initiatives in order to expand the treatment and diagnostic options. For instance, in 2018, the Australian government and Movember Foundation announced a partnership to combat prostate cancer by investing AUD 12 million in the ground-breaking new research teams focused on conducting life-saving prostate cancer researches and decreasing the number of deaths caused by the disease. Hence, owing to all the aforementioned factors, the market is anticipated to propel at high growth rates. However, the high cost of prostate cancer drugs and the low success rate of clinical trials are expected to hinder the market growth.
Scope of the Report
The prostate gland is located in the pelvis, below the bladder, and in front of the rectum. Prostate cancer begins when normal cells in the prostate begin to multiply uncontrollably. The scope of the study is limited to revenue generated by various diagnostic and therapeutic products used in the management of benign prostatic hyperplasia, prostatic adenocarcinoma, and small cell carcinoma, among other types of prostate cancer. The prostate cancer diagnostics and therapy market is segmented by type (benign prostatic hyperplasia, prostatic adenocarcinoma, small cell carcinoma, and other types), modality (diagnosis and treatment), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above-mentioned segments.
|Benign Prostatic Hyperplasia|
|Small Cell Carcinoma|
Key Market Trends
The Transrectal Ultrasound (TRUS) Segment is Expected to Grow at Rapid Pace
The transrectal ultrasound (TRUS) guided biopsy is also among the common diagnostic procedures performed for prostate cancer, which is still considered the viable option. It is quick and convenient to the provider, with a familiar approach to most urologists and a low risk of urinary retention. It is very useful to observe the abnormal areas of the prostate, size, and shape of the prostate. TRUS is considered a viable option in some cases as an important alternative for the early detection of prostate cancer. For patients who cannot undergo MRI procedures due to claustrophobia, metal implants, or lack of insurance coverage, TRUS is a good option with clinical benefits.
Philips is one of the major companies, which is advancing in both transrectal and transperineal biopsy. BK Medical is among the others, which has established itself well in PSA testing and TRUS as the primary diagnostic pathway for more than 25 years.
In recent years, the American Urology Association and the European Association of Urology recommended the TRUS biopsy, the most common and useful alternative transperineal approach. In several cases, the patients often suffer from associated diseases, where the TURS biopsy has a considerable edge over other procedures. Thus, it is widely known and accepted. At present, with several new approaches coming up with imaging, the growth of this segment is estimated to be steady during the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Retain the Largest Market Share During the Period of Forecast
Geographically, North America is anticipated to dominate the market share, owing to the factors such as the increasing prevalence of prostate cancer, coupled with the rising awareness and increasing research and development in this region. According to the American Cancer Society, in 2018, an estimate of 164,690 new prostate cancer cases was identified, and 29,430 deaths were reported in the United States.
The USFDA is taking steps to enhance the growth of the cancer therapy market by approving drugs, which are in the clinical phase, thus accelerating the clinical developments. Companies and research organizations are investing in R&D. Hence, the market is expanding at a fast pace.
The rising number of prostate cancer cases is creating huge opportunities for market players. The major market players are focusing on R&D activities to bring new and reliable treatments to the market. For instance, in March 2019, MiR Scientific launched tests for prostate and bladder cancer. In 2018, Clovis Oncology received Breakthrough Therapy Designation from the USFDA for Rubraca(rucaparib) for the treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Market players in Canada are focusing on various growth strategies such as new product launches, partnerships, mergers, and acquisitions. For instance, in February 2018, Janssen Pharmaceutical received Health Canada approval for a new indication for ZYTIGA (abiraterone acetate), broadening its use for the treatment of newly diagnosed metastatic prostate cancer. With the promising pipeline drugs, such as Apalutamide, the market in this region is expected to grow.
To understand geography trends, Download Sample Report
Several large drug and equipment manufacturers exist within the global prostate cancer diagnostic and therapy market, and their status as a major player lies primarily within specific product markets. Key players in the market include Abbott Laboratories, Astellas Inc., AstraZeneca, Bayer HealthCare AG, Cellanyx Diagnostics Inc., Dendreon Corporation, Ferring Pharmaceuticals, Ipsen Group, Sanofi-Aventis, Tolmar Inc, GE Healthcare, Siemens Healthineers, and F. Hoffmann-La Roche AG. Market players are constantly focusing on market expansion through innovative product launches. For instance, in February 2019, Blue Earth Diagnostics announced the first commercial production of Axumin(fluciclovine ) in Italy, with the first Italian patients being dosed. Axuminis, a novel molecular imaging agent, approved in the European Union for use in PET imaging to detect prostate cancer in men, those who are experiencing a suspected recurrence
In January 2021, Myovant partnered with Pfizer to commercialize its prostate cancer drug Orgovyx (relugolix), approved in December 2020.
In June 2020, Dr. Reddy launched the generic Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga (abiraterone acetate) for prostate cancer in the United States.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Aging Population and High Prevalence Rate of Prostate Cancer
4.2.2 Innovation in Drugs and Developments in Genomics and Proteomics
4.2.3 Increasing Government Initiatives for Cancer Awareness
4.3 Market Restraints
4.3.1 High Cost of Prostate Cancer Drugs
4.3.2 Low Success Rate of Clinical Trials
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Type
5.1.1 Benign Prostatic Hyperplasia
5.1.2 Prostatic Adenocarcinoma
5.1.3 Small Cell Carcinoma
5.1.4 Other Types
5.2 By Modality
188.8.131.52 Tissue Biopsy
184.108.40.206 Transrectal Ultrasound
220.127.116.11 Clinical Laboratory Examination
18.104.22.168.1 Prostate-specific Antigen Testing
22.214.171.124.2 Urine Testing
126.96.36.199 Diagnostic Imaging
188.8.131.52 Radiation Therapy
184.108.40.206.1 Hormone Therapy
220.127.116.11.3 Other Treatments
5.3.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle-East & Africa
5.3.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Astellas Pharma Inc.
6.1.3 AstraZeneca PLC
6.1.4 Bayer AG
6.1.5 Becton, Dickinson and Company
6.1.6 Dendreon Pharmaceuticals LLC
6.1.7 F. Hoffmann-La Roche Ltd
6.1.8 Hologic Inc.
6.1.9 Ipsen SA
6.1.10 Johnson & Johnson Services Inc.
6.1.11 Koninklijke Philips NV
6.1.12 Merck & Co. Inc.
6.1.13 Pfizer Inc.
6.1.15 Thermo Fisher Scientific
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Prostate Cancer Diagnostics and Therapy Market market is studied from 2018 - 2026.
What is the growth rate of Global Prostate Cancer Diagnostics and Therapy Market?
The Global Prostate Cancer Diagnostics and Therapy Market is growing at a CAGR of 6.1% over the next 5 years.
Which region has highest growth rate in Global Prostate Cancer Diagnostics and Therapy Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Prostate Cancer Diagnostics and Therapy Market?
North America holds highest share in 2020.
Who are the key players in Global Prostate Cancer Diagnostics and Therapy Market?
Bayer AG, AstraZeneca PLC, Sanofi-Aventis, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific are the major companies operating in Global Prostate Cancer Diagnostics and Therapy Market.